uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Update on Affibody molecules for in vivo imaging of targets for cancer therapy
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Biomedical Radiation Sciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Biomedical Radiation Sciences.ORCID iD: 0000-0001-6120-2683
2009 (English)In: Minerva biotecnologica (Testo stampato), ISSN 1120-4826, E-ISSN 1827-160X, Vol. 21, no 1, 21-30 p.Article in journal (Refereed) Published
Abstract [en]

An increasing specificity of the cancer treatment requires an accurate detection of cancer-associated molecular targets to avoid over- and undertreatment. Radionuclide molecular imaging is a pronitising way for visualisation of such targets. Affibody molecules (Affibody (R) molecules), small (7 kDa) robust scaffold proteins constitute a new promising class of high-affinity molecular probes for in vivo molecular imaging. Pre-clinical studies demonstrated a great potential of derivatives of Z(HER2:342) Affibody molecule to visualise expression of HER2 in tumour xenografts. Robustness of the Affibody scaffold enabled labelling in harsh conditions without loosing specificity of the HER2-binding. This paper provides an overview of the recent development of Affibody molecules. During the recent year, an important achievement was the development of site-specific labelling of Affibody molecules providing well-characterised uniform conjugates with defined biodistribution and targeting properties. The site-specific labelling was obtained either by an incorporation of chelators during peptides synthesis of Affibody molecules or by an introduction of a single cysteine in the originally cysteine-free Affibody scaffold and the use of a thiol-directed coupling. A feasibility of modification of the biodistribution of Affibody molecules by different chelators was another interesting fmding. This was demonstrated during development of mercaptoacetyl-containing peptide based chelators for Tc-99m-labelling of Affibody molecules. Several positron-emitting labels enabled the use of advantages of PET for Affibody-mediated radionuclide imaging. it was demonstrated that the rapid targeting of Affibody molecules is compatible with the use of such labels as Ga-68 and F-18.

Place, publisher, year, edition, pages
2009. Vol. 21, no 1, 21-30 p.
Keyword [en]
Affibody molecules, Neoplams, Radiopharmaceuticals, Radionuclide imaging, HER2
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-128331ISI: 000268685700003OAI: oai:DiVA.org:uu-128331DiVA: diva2:331274
Available from: 2010-07-22 Created: 2010-07-20 Last updated: 2017-12-12Bibliographically approved

Open Access in DiVA

No full text

Authority records BETA

Tolmachev, VOrlova, A

Search in DiVA

By author/editor
Tolmachev, VOrlova, A
By organisation
Biomedical Radiation Sciences
In the same journal
Minerva biotecnologica (Testo stampato)
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 659 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf